Sutent fails in advanced breast cancer

Tuesday 16 March 2010

Pfizer Inc has announced that two Phase 3 studies of Sutent (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The drug is currently approved for gastrointestinal stromal tumour and advanced renal cell carcinoma. The company announced the trial results on 11 March 2010.

 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States